Two additional indications for application of positron emission tomography (PET)/computed tomography (CT) in malignant lymphomas was approved by the Federal Joint Committee (G-BA) in May of 2018

Jun 2018

In May of 2018, the Federal Joint Committee (G-BA) approved two additional indications for application of PET/CT for management of malignant lymphomas:

Hodgkin's lymphoma in advanced stage after two cycles of guideline-based chemotherapy;
Malignant lymphomas in children and adolescents

These indications were added within amendment of the Directive for methods and examinations that are used in hospital settings and Directive methods of the contract medical care that are used in out-patient settings. That means, that procedures are now reimbursed in both hospital and out-patient settings within management of malignant lymphomas. Although, the decision has already been published at the web-site of G-BA, the amendments are not entered in force yet.
See full details in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

Matrix-associated autologous chondrocyte implantation on the knee joint reimbursed in Germany

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

The G-BA Innovation Committee recommends transfer to standard care for three projects in Germany

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Two more health apps obtained reimbursement in Germany

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Dutch Organization for Health Research and Development awarded eight projects under the "Healthcare Evaluation and Appropriate Use" program

Feb 2022

Dutch Organization for Health Research and Development, ZonMw awarded eight projects under the "Healthcare Evaluation and Appropriate Use" program, including two projects for geriatric care, two projects for cancer, per one project for cardiovascular, neurovascular, and dermatology care.

The 2022 list of medical technologies approved for innovation funding (NUB) released in Germany

Feb 2022

On January 28, 2022, the Institute for the Hospital Remuneration System (InEK) has published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2021. The medical technologies belonging to the cardiovascular, ENT, eHealth, gastrointestinal, neuromodulation, neurovascular, orthopedic, and other technology groups obtained positive status 1.